US Market Report for Continuous Glucose Monitoring 2017 - MedCore
The U.S. continuous glucose monitoring (CGM) market can be segmented by setting, yielding two segments: professional CGM and personal CGM. In 2016, the largest segment in the total CGM market was the personal CGM segment. Growth is expected to continue over the forecast period and will be driven by favorable reimbursement, technological innovation and increased uptake of personal CGM among type 1 diabetics and insulin-dependent type 2 diabetics. Professional CGM is typically used in retrospective sessions initiated by physicians, during which a patient wears a CGM sensor for several days to a week, but is ‘blinded’ to the real-time CGM data and must adhere to frequent self-monitoring of blood glucose (SMBG) using traditional blood glucose meters. Additionally, the patient must maintain a record of their daily dietary intake and activity during the time that the sensor is worn. At the end of the session, the patient returns to their physician to remove the sensor and retrospectively analyze the glucose data that was collected. The ‘blinded’ aspect of professional CGM allows physicians to more easily assess their patient’s behavior because their actions are not influenced by ‘real-time’ glucose data, as is the case with personal CGM products.
Continuous glucose monitoring (CGM) allows for a more accurate reading of how blood glucose levels fluctuate throughout the day by measuring interstitial glucose levels on a continuous basis and estimating blood glucose levels based on these readings. A CGM system is typically made up of three components: a glucose sensor, transmitter and receiver. The sensor is inserted under the skin into the interstitial fluid and held with an adhesive. Sensors are typically sold in groups of four and are labeled for six to seven days of use, depending on the manufacturer. A transmitter takes the glucose reading from the sensor and wirelessly sends it to a small, hand-held receiver. If glucose levels are too low or high, the receiver warns the patient. Some manufacturers have even built-in a threshold audible alarm as a fixed safety feature when the patient approaches levels below 55 mg/dL, at which point the patient is still interactive but severely hypoglycemic.